The investigators linked 73,637 MIMIC-IV admissions to chest radiographs, radiology reports, 12-lead ECG recordings and laboratory tests from the first 48 hours to evaluate in-hospital detection of lung cancer and heart failure. They excluded prior cases for each disease and compared single-source models, gradient boosting on laboratory data, and three fusion strategies: early fusion, late fusion and attention-based fusion. The cohort contained 1.7% with coded lung cancer and 15.6% with coded heart failure.
Attention-based fusion produced the best discrimination for both targets in internal validation. For lung cancer, attention fusion achieved AUROC 0.833 (95% CI 0.809–0.859) compared with 0.753 for gradient boosting on laboratory variables. For heart failure, attention fusion reached AUROC 0.885 (95% CI 0.878–0.892) versus 0.794 for laboratory gradient boosting; early and late fusion returned similar performance to attention fusion. The study team reported these differences as statistically significant in their comparisons.
Data contribution varied by disease. The authors reported that laboratory data and radiology reports were the largest contributors to lung cancer prediction, while the ECG provided the strongest signal for heart failure. Chest radiographs were included in the fusion, and radiology report text added incremental information for detecting cancer-coded admissions. The source did not report detailed per-feature effect sizes beyond these attribution summaries.
The study applied two explanation-fidelity checks. First, a deletion test was performed and passed, indicating that removing high-attribution inputs degraded model output as expected. Second, a weight-randomisation check assessed whether absolute attributions depended on learned model weights. The ECG attributions passed the weight-randomisation check, but laboratory attributions failed this particular test. The authors therefore advised running explanation checks per data source and per similarity or attribution measure rather than assuming uniform faithfulness across modalities.
Investigators audited model discrimination across sex, age, race and ethnicity, and insurance categories. They reported a decline in discrimination for heart failure with increasing patient age. The source did not provide exhaustive subgroup AUROCs for every demographic slice in the abstract, but did emphasize monitoring older patients in deployment given this observed performance drop. The study team noted fairness auditing as part of their evaluation pipeline.
To assess multi-site learning, the authors simulated five unequal hospitals and compared local, centralised pooled and federated training approaches. For heart failure, federated training recovered 95% of the centralised pooled gain relative to local models. For the rarer lung cancer outcome, federated averaging (FedAvg) recovered 51% of the pooled benefit, while FedProx—an algorithm that constrains client drift—recovered 82%. The report indicates that federated algorithms differed in their ability to retain pooled performance for rare outcomes, and that FedProx retained more benefit than FedAvg for lung cancer in this simulation.
This is a retrospective, single-centre linkage study using publicly available MIMIC collections; the authors acknowledged the need for external validation. They archived a pre-specified analysis plan and released code v1.0-protocol at the cited Zenodo record. The dataset components used (MIMIC-IV admissions, MIMIC-CXR images and reports, and MIMIC-IV-ECG) are available to credentialed users under PhysioNet agreements; under those agreements the authors cannot share patient-level data.
Limitations explicitly stated by the authors include the single-centre design, reliance on coded diagnoses which set disease prevalence at 1.7% for lung cancer and 15.6% for heart failure, and challenges in federated recovery for a rare outcome. The abstract did not report detailed per-feature coefficients, nor did it present external validation results; those items remain outstanding. The authors recommended routine explanation checks for each input modality and suggested monitoring performance in older patients if models are deployed.
Data availability, code and the pre-specified analysis plan were provided by the authors at their archived links. Competing interests were declared as none. External validation across independent hospital systems is the next documented step before considering broader clinical use.